1. Scrip

Lilly Scores With Orforglipron In Diabetes, Generating Excitement For Obesity

 
• By Alaric DeArment

The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.

magnifying glass over GLP-1 written on scrap of paper. other paper scraps read "obesity," "semaglutide" "weight loss"
(Shutterstock)

Eli Lilly stands to shake up the market for GLP-1 receptor agonists with positive pivotal data in type 2 diabetes for its oral drug, orforglipron, which also provide an encouraging sign for the drug in patients with obesity. The Phase III results also give the company a head start on its biggest competitor, Denmark-based Novo Nordisk.

Key Takeaways
  • Eli Lilly announced positive topline Phase III data for the oral GLP-1 receptor agonist orforglipron in type 2 diabetes, with the drug producing strong A1C...

Lilly announced topline data 17 April from the ACHIEVE-1 trial comparing orforglipron against placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Scrip

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.